Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal

British Journal of Haematology

Volumn 95, Issue 3, 1996, Pages 501-507

  Albrecht, Tarja ^a   Schwab, Renate ^a   Henkes, Martin ^a   Peschel, Christian ^a   Huber, Christoph ^a   Aulitzky, Walter E ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Apoptosis; CML; DNA damage; Primary cells

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0029959087     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1934.x     Document Type: Article

References (22)

1. Amos, T.A.S., Lewis, J.L. Grand, F.H., Gooding, R.P., Goldman, J.M. & Gordon, M.Y. (1995) Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation. X-irradiation and glucocorticoids. British Journal of Haematology, 91, 387-393.
2. Bedi, A., Barber, J.P., Bedi, G.C., el Deiry, W.S., Sidransky, D., Vala, M.S., Akhtar, A.J., Hilton, J. & Jones, R.J. (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood, 86, 1148-1158.
3. Bedi, A., Zehnbauer, B.A., Barber, J.P., Sharkis, S.J. & Jones, R.J. (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood, 83, 2038-2044.
4. Ben-Neriah, Y., Daley, G.Q., Mes-Masson, A.M., Witte, O.N. & Baltimore, D. (1986) The chronic myelogenous leukemia specific p210 protein is the product of the bcr-abl hybrid gene. Science, 233, 212-215.
5. Carlo Stella, C., Mangoni, L., Piovani, G., Almici, C., Garau, D., Caramatti, C. & Rizzoli, V. (1991) In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplantation, 8, 265-273.
6. Chapman, R.S., Whetton, A.D., Chresta, C.M. & Dive, C. (1995) Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. Molecular Pharmacology, 48, 334-343.
7. Collins, M.K.L., Marvel, J., Malde, P. & Lopez-Rivas, A. (1992) Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. Journal of Experimental Medicine, 176, 1043-1051.
8. Cortez, D., Kadlec, L. & Pendergast, A.M. (1995) Structural and signaling requirements for BCR-ABL-medialed transformation and inhibition of apoptosis. Molecular and Cellular Biology, 15, 5531-5541.
9. Douay, L., Hu, C., Giarratana, M.C., Bouchet, S., Conlon, J., Capizzi, R.L. & Gorin, N.C. (1995) Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood, 86, 2849-2855.
10. Eaves, A.C., Cashman, J.D., Gaboury, L.A., Kalousek, D.K. & Eaves, C.J. (1988) Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proceedings of the National Academy of Sciences of the United State of America, 83, 5306-5310.
11. Finney, R., McDonald, G.A. & Baikie, A.G. (1972) Chronic granulocytic leukemia with Ph1-negative cells in the bone marrow and a ten-year remission after busulfan hypoplasia. British Journal of Haematology, 23, 283-285.
12. Gorczyca, W., Gong, J., Ardelt, B., Traganos, F. & Darzynkiewicz, Z. (1995) The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Research, 53, 3186-3192.
13. Holdrinet, R.S.G., Pennings, A., van Egmond, J., Wessela, J.M.C. & Haanen, C. (1983) DNA-flow cytometry of blood and bone marrow in chronic myelogenous leukemia. Acta Hematologica, 69, 98-107.
14. Lotem, J. & Sachs, L. (1993) Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth and Differentiation, 4, 41-47.
15. Nieborowska Skorska, M., Skorski, T., Ratajczak, M.Z., Szczylik, C., Malaguarnera, L. & Calabretta, B. (1993) Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells. Folia Histochemica Cytobiologica, 31, 161-167.
16. Rowley, J.D. (1973) A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290-293.
17. Sanchez Garcia, I. & Grutz, G. (1995) Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proceedings of the National Academy of Sciences of the United State of America, 92, 5287-5291.
18. Santucci, M.A., Anklesaria, P., Laneuville, P., Das, I.J., Sakakeeny, M.A., FitzGerald, T.J. & Greenberger, J.S. (1995) Expression of p210 bcr/abl increases hematopoietic progenitor cell radiosensitivity. International Journal of Radiation Oncology and Biological Physics, 26, 831-836.
19. Schwab, R., Peschel, C., Desprès, D., Derigs, G., Fischer, T., Huber, C. & Aulitzky, W.E. (1995) Deficient cell cycle control in myeloid cells of patients with newly diagnosed chronic myeloid leukemia. Cytokines and Molecular Therapy, 1, 281-288.
20. Sirard, C., Laneuville, P. & Dick, J.E. (1994) Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood, 83, 1575-1585.
21. Stryckmans, P.A., Debuscher, L. & Collard, E. (1976) Cell kinetics in chronic granulocytic leukemia. Cancer Research, 36, 3034-3038.
22. Williams, G.T. (1991) Programmed cell death: apoptosis and oncogenesis. Cell, 65, 1097-1098.